OncoMatch/Clinical Trials/NCT05245786
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Is NCT05245786 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Copper Cu 64 Anti-CEA Monoclonal Antibody M5A for locally advanced rectal carcinoma.
Treatment: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A — This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who are undergoing chemotherapy and radiotherapy. Using 64Cu-labeled M5A positron emission tomography imaging may play a significant role in imaging patients with colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: CEACAM5 expression
Disease stage
Required: Stage IIIA, IIIB, IIIC (AJCC v8)
locally advanced rectal cancer (T3, T4 and N0 or N plus [+])
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify